

CURRICULUM VITAE

Jeffrey E. Lancet, M.D.

Current Position: Senior Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
12902 Magnolia Dr., SRB4
Tampa, Florida 33612
(813) 745-6841
(813) 745-3071 Fax
Jeffrey.Lancet@moffitt.org

Current Academic: Professor
Department of Oncologic Sciences
University of South Florida

Education:

1988-1992: **M.D.** S.U.N.Y. Upstate Medical College at Syracuse, New York

1984-1988: **B.A.** University of Rochester, Rochester, New York
Biology, Psychology (Cum Laude)

Postgraduate Training and Fellowship Appointments:

2014 Fellow – The Leadership Academy at Moffitt Cancer Center (Physician Leadership Institute)

1996-1999: Hematology/Oncology Clinical and Research Fellowship - University of Rochester School of Medicine and Dentistry, Rochester, NY

1995-1996: Chief Resident & Instructor in Medicine - St. Mary's Hospital, University of Rochester School of Medicine and Dentistry, Rochester, NY

1993-1995: Residency - Internal Medicine, Strong Memorial Hospital, University of Rochester School of Medicine and Dentistry, Rochester, NY

1992-1993: Internship - Internal Medicine, Strong Memorial Hospital, University of Rochester School of Medicine and Dentistry, Rochester, NY

Jeffrey E. Lancet, M.D.

Academic Appointments and Employment:

- 7/1/2013 to Present: Senior Member, Tenure status, H. Lee Moffitt Cancer Center & Research Institute, Department of Interdisciplinary Oncology, Tampa, Florida
- 9/2007 – 7/2013 Associate Member, Tenure status, H. Lee Moffitt Cancer Center & Research Institute, Department of Interdisciplinary Oncology, Tampa, Florida
- 9/2004 – 8/2007 Assistant Professor of Medicine, Tenure status, H. Lee Moffitt Cancer Center & Research Institute, Department of Interdisciplinary Oncology, Tampa, Florida
- 9/2004 – present Admitting Physician, H. Lee Moffitt Cancer Center & Research Institute
- 8/2001 - 8/2004 Assistant Professor of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY
- 1999 - 2004 Admitting Physician, Strong Memorial Hospital, Rochester, NY

Medical License:

Florida Status - Active since 2004

Board Certifications:

- 2000 Medical Oncology
1999 Hematology
1996 American Board of Internal Medicine

TEACHING EXPERIENCE

University Courses:

- 2007-present **Clinic Supervisor**, Hematology Clinic, Interdisciplinary Oncology Clerkship (BCC 8117), College of Medicine, University of South Florida
- 2004-2007 **Course Lecturer**, Pathobiology of Neoplasia (NGR 6142), College of Nursing, University of South Florida, Tampa, FL. *Acute and Chronic Leukemias*

Jeffrey E. Lancet, M.D.

2003-2004 **Course Lecturer**, Disease Processes and Therapeutics I, University of Rochester College of Medicine, Rochester, NY. *Acute Leukemias*

2001-2004 **Case-based Learning Facilitator**, Molecules to Cells Course, University of Rochester College of Medicine, Rochester, NY. *Oncogenes, Apoptosis, and Clinical Trials*

Other Courses & National Symposia:

Nov 2013 **Chairman**, *Applying Emerging Evidence in the Management of Myelodysplastic Syndromes and Acute Myeloid Leukemia*. Tampa, Florida. (USF-sponsored CME event)

2007-present **Course Director** *Clinical Breakthroughs and Challenges in Hematologic Malignancies*, Lake Buena Vista, Florida (joint USF/Moffitt/FLASCO local/regional CME Event)

4-2007 **Moderator**, *Oncology Best Practices 2007* Community-based learning. "Advances in Hematologic Malignancies" Tampa, Florida

2010-present **Lecturer**, Clinical Trials Workshop Course for Graduate Students and Post-Doctoral Fellows, H. Lee Moffitt Cancer Center (supervisor, Douglas Cress, PhD)

2005-present **Lecturer**, Hematology/Oncology Fellows Lecture Series, H. Lee Moffitt Cancer Center & Research Institute. *Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia, Acute Myeloid Leukemia*

2004-present Inpatient Teaching Attending Rounds, Hematology-Oncology inpatient ward, H. Lee Moffitt Cancer Center & Research Institute

1999-2004 Inpatient Teaching Attending Rounds, Hematology-Oncology inpatient ward, Strong Memorial Hospital, University of Rochester, Rochester, NY

1997-2004 **Instructor**, Second-year medical student hematology clerkship laboratory, University of Rochester College of Medicine, Rochester, NY

1996-2004 **Instructor**, First-year medical student histology laboratory, University of Rochester College of Medicine, Rochester, NY

1994-1995 **Coordinator**, Weekly Acute Care Conference Lectures for Medical Residents, University of Rochester, Department of Medicine, Rochester, NY.

Jeffrey E. Lancet, M.D.

Post-Doctoral Training:

(b) (6)



HONORS AND AWARDS

2008 Recipient of the Clinical Trial Award for the Highest Number of Investigator-Initiated Trials for H. Lee Moffitt Cancer Center and Research Institute

2007-2009 Recipient of the Clinical Trial Award for the Highest Accrual of Patients

Jeffrey E. Lancet, M.D.

on Therapeutic Clinical Trials in Hematological Malignancies for H. Lee Moffitt Cancer Center and Research Institute

2005, 2013 Nomination for “Physician of the Year” H. Lee Moffitt Cancer Center and Research Institute

1988 Cum Laude Graduate, University of Rochester, Rochester, New York

RESEARCH SUPPORT

CURRENT

External Grants:

Account # 1R01CA168677-01A1
Name and Role: **Jeffrey Lancet, co-investigator** (PI: Martine Extermann, MD)
Source: NIH/NCI
Title: Decision Models to Compare Treatments in Older Patients with AML
% Effort: 10%
Direct Costs: \$939,800
Award: \$1,373,529

Clinical Trials: Principal Investigator (PI)

Name and Role: **Jeffrey Lancet –PI**
Dates: 8/2013 – Present
Source: MCC
Title: MCC 17302: A Phase II Study Evaluating the Oral Smoothened Inhibitor PF-04449913 in Patients with Myelodysplastic Syndrome
Objective: **Investigator-initiated treatment research trial**
Planned Patient total: 35
MCC Accrual: 9
Total Amount: (b) (4)

Name and Role: **Jeffrey Lancet – National and Institutional PI**

Dates:
Source:
Title:

Objective:
Planned Patient total
MCC Accrual:

Jeffrey E. Lancet, M.D.


Total Amount:
Per Patient:
Name and Role:
Dates:
Source:
Title:

Objective:
Planned Patient total
MCC Accrual (to date)
Per Patient:




Name and Role:
Dates:
Source:
Title:

Objective:
Planned Patient total
MCC Accrual (to date)
Per Patient:




Name and Role:
Dates:
Source:
Title:

Objective:
Planned Patient total:
MCC Accrual (to date)
Per Patient:



Name and Role:
Dates:
Source:
Title:

Objective:
Planned Patient total:
MCC Accrual (to date):
Per Patient:



COMPLETED

External Grants:

Award #: 5 P30 CA076292-11
Name and Role: Jeffrey Lancet -PI
Dates: 02/1/09 – 01/31/11
Source: National Institutes of Health
Title: NIH-ASCO Cancer Foundation Clinical Investigator Team Leadership Award
% Effort: 12%
Total direct costs: \$57,594
Total Amount: \$96,182

Award #: R-6030-04 (University of Rochester)
Name and Role: Jane Liesveld – PI, Jeffrey Lancet – Co-PI
Dates: 10/1/03 – 09/30/05
Source: Leukemia & Lymphoma Society
Title: Effect of Farnesyltransferase Inhibition in AML and MDS
% Effort: 16%
Total direct costs: (b) (4)
Total Amount: (b) (4)

Contracts:

Account #: 19-15053-01-03
Name and Role: Jeffrey Lancet - PI
Dates: 08/2006 – Present
Source: NCI/CTEP Translational Research Initiative
Title: MCC 14796: Phase I Dose-Escalation Study of R11577 (Tipifarnib) plus PS-341 (bortezomib) in Relapsed or Refractory Acute Leukemias
% Effort: N/A
Total Direct Costs: \$31,290
Total Amount: \$51,316

Clinical Trials: Principal Investigator

Account #: 10-14398-99-01
Name and Role: **Jeffrey Lancet – National and Institutional PI**
Dates: 5/2011 – 7/2012
Source: NCI-CTEP (Funded through institutional N-01 contract)
Title: MCC 16572: Phase 2 Trial of R115777 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Objective: **Investigator-initiated treatment research trial**
Planned Patient total: 35
MCC Accrual: 8
Per Patient: \$6,393

Name and Role: **Jeffrey Lancet – PI**
Dates: 10/2007 – 12/2012
Source: MCC
Title: MCC 15025: Pilot trial of a WT-1 analog peptide vaccine in patients with myeloid neoplasms
Objective: **Investigator-initiated treatment research trial**
Planned Patient total: 10
MCC Accrual: 13
Total Amount: (b) (4)
Per Patient: (b) (4)

Name and Role: **Jeffrey Lancet – PI**
Dates: (b) (4)
Source: (b) (4)
Title: (b) (4)
Objective: (b) (4)
MCC Accrual: (b) (4)
Total Amount: (b) (4)
Per Patient: (b) (4)

Name and Role: **Jeffrey Lancet – Institutional PI**
Dates: (b) (4)
Source: (b) (4)
Title: (b) (4)

Jeffrey E. Lancet, M.D.

Objective:
Planned Patient total
MCC Accrual:
Per Patient:



Name and Role: Jeffrey Lancet – National and Institutional PI
Dates: 05/2009 – 6/2013
Source: SWOG
Title: S0535: A Phase II Study Of Atra, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Objective: Investigator-initiated cooperative group treatment research trial
Planned Patient total: 70

Name and Role: Jeffrey Lancet – Institutional PI
Dates: 10/2009 – 00/2011
Source: SWOG
Title: MCC 15992: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
Objective: SWOG treatment research trial
Planned Patient total: 300
MCC Accrual: 5

Name and Role: Jeffrey Lancet – National and Institutional PI
Dates:
Source:
Title:



Objective:
Planned Patient total
MCC Accrual:
Per Patient:

Name and Role: Jeffrey Lancet – National and Institutional PI
Dates:
Source:
Title:



Objective:
Planned Patient total:
MCC Accrual:

Jeffrey E. Lancet, M.D.

Per Patient:

(b) (4)

Name and Role:

Jeffrey Lancet – National and Institutional PI

Dates:

Source:

Title:

(b) (4)

Objective:

Planned Patient total

MCC Accrual

Per Patient:

Name and Role:

Jeffrey Lancet – National and Institutional PI

Dates:

7/2008 – 3/2009

Title:

MCC 15332. A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previously Untreated AML

Objective:

Sponsored treatment research trial

Planned Patient total: 211

MCC Accrual: 7

Per patient

(b) (4)

Name and Role:

Jeffrey Lancet – National and Institutional PI

Dates:

Source:

Title:

(b) (4)

Objective:

MCC Accrual:

Per Patient:

Name and Role:

Jeffrey Lancet – National and Institutional PI

Dates:

Source:

Title:

(b) (4)

Objective:

Jeffrey E. Lancet, M.D.

Planned Patient total
MCC Accrual:
Per Patient:




(b) (4)

Name and Role: Jeffrey Lancet – Institutional PI
Dates: 05/2007 - Present
Source: SWOG
Title: MCC 15154: A Phase II Study of Lenolidomide (Revlimid) (NSC-703813) For Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
Objective: SWOG treatment research trial
Planned Patient total: 37
MCC Accrual: 11

Name and Role: Jeffrey Lancet – Institutional PI
Dates: 05/2007 – 8/2008
Source: SWOG
Title: MCC 15036: A Phase II Study of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Objective: SWOG treatment research trial
Planned Patient total: 37
MCC Accrual: 6


Name and Role: Jeffrey Lancet – National and Institutional PI
Dates:
Source:
Title:



Objective:
Planned Patient total:
MCC Accrual:
Per Patient:

(b) (4)

Name and Role: Jeffrey Lancet – Institutional PI and co-author of trial
Dates:
Source:
Title:



Objective:
Planned Patient total:
MCC Accrual:

(b) (4)

Jeffrey E. Lancet, M.D.

Per Patient:

(b) (4)

Account #: 10-14398-99-01

Name and Role: **Jeffrey Lancet – National and Institutional PI** (clinical trial),
Institutional N-01 Contract (to fund clinical trial),
PI – Daniel Sullivan, MD

Dates: 08/2006 – 12/2008

Source: NCI/CTEP

Title: MCC 14796: Phase I Dose-Escalation Study of R11577 (Tipifarnib)
plus PS-341 (bortezomib) in Relapsed or Refractory Acute Leukemias

Objective: **Investigator-initiated translational research trial**

% Effort: 5%

Planned Patient total: 27

MCC Accrual: 19

Total Direct Costs: \$2,600 per patient

Total Amount: \$4,600 per patient

Account # 84-14604-01-01

Name and Role: **Jeffrey Lancet - PI**

Dates:

Source:

Title:

(b) (4)

Objective:

Patient Total

Total Direct Costs:

Total Amount:

Name and Role: **Jeffrey Lancet – National and Institutional PI**

Dates:

Source:

Title:

(b) (4)

Objective:

Planned Patient total

MCC Accrual:

Per Patient:

Name and Role: **Jeffrey Lancet – National and Institutional PI**

Dates:

Source:

Title:

(b) (4)

Jeffrey E. Lancet, M.D.

Objective:
Planned Patient total:
MCC Accrual:
Per Patient:

(b) (4)

Name and Role: Jeffrey Lancet – Institutional PI

Dates:
Source:
Title:

(b) (4)

Objective:
Planned patient Total
MCC Accrual:
Per Patient:

Name and Role: Jeffrey Lancet – National and Institutional PI

Dates:
Source:
Title:

(b) (4)

Objective:
Planned Patient total
MCC Accrual:
Per Patient:

Name and Role: Jeffrey Lancet – Institutional PI

Dates: 08/2005 - 02/2006
Source: SWOG
Title: MCC 14486: Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older

Objective: SWOG treatment research trial.
Planned Patient total: 348
MCC Accrual: 13

Name and Role: Jeffrey Lancet - Institutional PI

Dates: 06/2005 - 01/2006
Source: NCI
Title: MCC 14492: Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma

Objective: NCI sponsored treatment research trial.
Patient Total: 2 (early termination by sponsor)

Jeffrey E. Lancet, M.D.

Name and Role: Jeffrey Lancet – National and Institutional PI

Dates:

Source:

Title:

Objective:

Planned Patient total

MCC Accrual:

Per Patient:

(b) (4)

SERVICE

H. Lee Moffitt Cancer Center Service

Administrative Appointments:

2013-present	Chief of Medicine Services , Moffitt Cancer Center
2005-2012	Head of Clinical Research , Malignant Hematology Division
2006-present	Leukemia Section Head , Malignant Hematology Division

Committees:

9/2013 – Present	Member , Medicine Safety Committee - Monthly
1/2012 – Present	Member , Moffitt Clinical Research Action Committee -Monthly
7/2011 – Present	Member/Chair Moffitt Conflict of Interest Committee – Monthly (Chair, 6/2013)
3/2011 – Present	Member , Moffitt Appointment, Promotion, and Tenure Committee - weekly
2010 – 2011	Member , Grand Rounds Steering Committee
2008 – 2011	Member , Clinical Research Governance Committee
3/2006 - 6/2011	Vice-chair , Protocol Monitoring Committee
2005-2007	Member , Clinical Investigations Steering Committee

University of Rochester Service

Committees:

2000 – 2004	Member , University of Rochester Peer Review Committee
-------------	---

Professional

July 2015	Member , Oncology Drug Advisory Committee of the US Food & Drug Administration
-----------	--

Jeffrey E. Lancet, M.D.

- 2014-present **Abstract Reviewer**, American Society of Hematology (**Chair, 8/2015**)
- June 2014 **Chair**, Leukemia/MDS/Transplant Oral Abstract Session, American Society of Clinical Oncology Annual Meeting.
- July 2012-2014 **Member/Track Chair**, Education Committee, American Society of Clinical Oncology (**Chair, 7/2013**)
- Jan 2010-Present **Member, Editorial Board**, Journal of Clinical Oncology
- Nov 2008-2009 **Track Chair**, Scientific Program Committee, American Society of Clinical Oncology
- Jan 2008–Present **Associate Editor**, *Clinical Lymphoma, Myeloma, & Leukemia*
- October 2007 **Member**, Senior Editorial Board Member, *Clinical Leukemia Journal*
- June 2007-June 2010 **Member**, Scientific Program Committee, American Society of Clinical Oncology
- June 2007–Dec 2009 **Associate Editor**, *Cancer Investigation*
- 2006 – Present **Member**, NCCN Acute Myeloid Leukemia Panel
- 2005 – 2006 **Abstract Reviewer** – American Society of Hematology Annual Meeting
- 2001 - Present **Ad Hoc Reviewer** – *American Journal of Hematology, Blood, Cancer, Journal of Clinical Oncology, Leukemia, Leukemia Research*
- Community**
- October 2011 **Participating Faculty and Keynote Speaker:** Leukemia & Lymphoma Society, “Living with a Blood Cancer: a Patient Centered Symposium”, Tampa FL
- October 2009 **Participating Faculty:** Aplastic Anemia and MDS International Foundation, Patient Education Symposium, Tampa FL
- 2007 - 2008 **Participating Faculty:** Leukemia, Lymphoma, Myeloma and Bone Marrow Transplantation: An educational symposium for patients and families. H. Lee Moffitt Cancer Center and Research Institute

PROFESSIONAL ASSOCIATION MEMBERSHIPS

- 1999 - Present **Member**, American Society of Hematology

Jeffrey E. Lancet, M.D.

1999 - Present **Member**, American Society of Clinical Oncology
1999 - Present **Member**, American Association of Cancer Research

PEER-REVIEWED PUBLICATIONS

Original Scientific Articles

1. Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepe M, Padron E, Epling-Burnette PK, **Lancet JE**, List AF, Komrokji RS. *Impact of tobacco usage on disease outcome in myelodysplastic syndromes*. Leuk Res 2015 (Epub ahead of print)
2. Brayer J, **Lancet JE**, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. *WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides*. Am J Hematol 2015 (Epub ahead of print)
3. Garcia-Manero G, Khoury HJ, Jabbour E, **Lancet JE**, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, List AF, Kantarjian H, Komrokji RS. *A phase I study of oral ARRY-614, a 38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate 1 risk myelodysplastic syndromes*. Clin Cancer Res 2015; 21:985
4. Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, **Lancet JE**, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. *A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution*. Acta Haematol 2015; 133:249-256.
5. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, **Lancet J**, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. *Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS clinical research consortium*. Cancer 2015; 121:876
6. **Lancet JE**, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. *A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia*. Haematologica 2015; 100:231
7. Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, **Lancet JE**, Papenhausen PR, Zhang L, Pinilla-Ibarz J. *Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia*. Int J Hematol 2014;100:567-574.
8. Horna P, Zhang L, Sotomayor EM, **Lancet JE**, Moscinski LC. *Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid*. Am J Clin Pathol 2014; 142:546-552.

9. Tao J, Zhang X, **Lancet J**, Bennett JM, Cai L, Papenhausen P, Moscinski L, Zhang L. *Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.* Cancer Genet 2014; 207:489-494.
10. Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, **Lancet J**, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. *ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.* Blood 2014; 123: 3675-3677.
11. Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, **Lancet JE**. *Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.* Am J Hematol 2014; 89:809-812.
12. **Lancet JE**, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. *Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.* Blood 2014; 123:3239-3246
13. Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, **Lancet J**, Fernandez H, List A, Anasetti C, Field T. *Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.* Biol Blood Marrow Transplant 2014; 20:776-780.
14. Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, **Lancet JE**, Komrokji RS. *Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.* Leuk Res 2014; 38:443-446.
15. Horna P, Pantazopoulos P, **Lancet JE**, Moscinski LC, Zhang L. *Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous leukemia: mimicking recurrent B-lymphoid blast crisis.* Leuk Lymphoma 2014; 55:1952-1954
16. Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, **Lancet JE**, List AF, Komrokji RS. *Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.* Clin Lymphoma Myeloma Leuk 2013; 13:711-715
17. Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, **Lancet JE**, Fernandez HF, Djulbegovic B, Kumar A. *Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.* Br J Haematol 2013; 163:315-325.
18. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebt S, Kantarjian HM, Ravandi F, **Lancet JE**. *Phase I*

- clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.* Leuk Res. 2013; 37:1461-1467.
19. Komrokji RS, Raza A, **Lancet JE**, Ren C, Taft D, Maniar M, Wilhelm F, List AF. *Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.* Br J Haematol. 2013; 162:517-524
20. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, **Lancet J**, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. *GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.* Blood. 2013; 121:5068-5077.
21. Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, **Lancet JE**, List AF, Komrokji RS. *Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.* Am J Hematol 2013; doi: 10.1002/ajh.23454. Am J Hematol 2013 Jul; 88: (7) 566-570 [Epub ahead of print].
22. Duong VH, Jaglal MV, Zhang L, Kale V, **Lancet JE**, Komrokji RS, List AF. *Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.* Leuk Res 2013; 37:300-304.
23. Duong VH, **Lancet JE**, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. *Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.* Leuk Res 2013; 37:510-515.
24. Sekeres MA, **Lancet JE** (co-first author), Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. *Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.* Haematologica 2013; 98:119-128.
25. Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, **Lancet JE**, List AF. *Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.* Am J Hematol 2012; 87:1006-1009.
26. Komrokji RS, **Lancet JE**, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. *Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.* Blood. 2012; 120:3419-3424.
27. Sekeres MA, Tiu RV, Komrokji R, **Lancet J**, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. *Phase 2 study of the lenalidomide and azacitidine*

combination in patients with higher-risk myelodysplastic syndromes. Blood 2012;120:4945-4951.

28. Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, **Lancet J**, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. *Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.* Support Care Cancer 2013; 21:1097-1103.
29. Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Mayer LD, Swenson CE, Chiarella MT, Louie AC, **Lancet JE**. *Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.* Leukemia Research 2012; 36:1283-1289.
30. Komrokji RS (CL-Hematol Malig), Corrales-Yepe M, Ali NA, Kharfan-Dabaja M, Padron E, Fields T (ET-Womens Onc), **Lancet JE**, List AF. *Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.* Cancer 2012; 118:2659-2664.
31. Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, **Lancet J**, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. *A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.* Proteomics Clin Appl. 2011; 5:383-396.
32. Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, **Lancet J**, List AF. *Telomere length in myelodysplastic syndromes.* Leuk Lymphoma 2011; 8:1528-1536.
33. **Lancet JE**, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. *A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.* Leukemia 2011; 25:1808-1814.
34. Sekeres MA, Gundacker H, **Lancet J**, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF, *A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.* Blood 2011;118:523-528.
35. Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, **Lancet JE**. *Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.* Cancer. 2011 April 1; 117(7):1463-1469
36. Price SL, **Lancet JE**, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. *Salvage chemotherapy regimens for acute*

myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011; 353:301-304.

37. Feldman EJ, **Lancet JE**, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. *First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.* J Clin Oncol. 2011; 29:979-985.
38. **Lancet JE**, Duong VH, Winton EF, Stuart RK, Burton MK, Zhang S, Cubitt CL, Blaskovich MA, Wright JJ, Sebti SM, Sullivan DM. *Phase I Clinical-Pharmacodynamic Study of Farnesyltransferase Inhibitor Tipifarnib in Combination with Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.* Clin Cancer Res. 2011; 17:1140-1146.
39. Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, **Lancet JE**, Komrokji RS, Kharfan-Dabaja MA. *Hepatobiliary manifestations of acute myeloid leukemia.* Leuk Res. 2011; 35:e81-83.
40. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, **Lancet JE**, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. *Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.* Br J Haematol 2010; 151:430-434.
41. Field T, Perkins J, Huang Y, Kharfan-Dabaja M, Alsina M, Ayala E, Fernandez HF, Janssen W, **Lancet J**, Perez L, Sullivan D, List A, Anasetti C. *5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.* Bone Marrow Transplant 2010; 45:255-260.
42. **Lancet JE**, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. *Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.* Leukemia 2010; 24:699-705.
43. Marcelletti JF, Multani PS, **Lancet JE**, Baer MR, Sikic BI. *Leukemic blast and natural Killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.* Leuk Res. 2009;33:769-774.
44. **Lancet JE**, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. *A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.* Leuk Res. 2009;33:1055-1061.
45. Raza A, Galili N, Smith S, Godwin J, **Lancet J**, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. *Phase I multicenter dose-escalation study of ezatiostat hydrochloride*


(TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. *Blood* 2009; 113:6533-6540.

46. Raponi M, **Lancet JE**, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Lowenberg B, Stone RM, De Porre P, Wang Y, Karp JE. *A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia*. *Blood*. 2008;111:2589-2596.
47. Karp JE, Smith BD, Gojo I, **Lancet JE**, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. *Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor – risk features*. *Clin Cancer Res*. May 2008; 15:3077-3082.
48. Raponi M, Harousseau JL, **Lancet JE**, Lowenberg B, Stone R, Zhang Y, Rackoff W, Wang Y, Atkins D. *Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia*. *Clin Cancer Res*. 2007;13:2254-2260.
49. **Lancet JE**, List AF, Moscinski LC. *Treatment of deletion 5q acute myeloid leukemia with lenalidomide*. *Leukemia*. 2007; 21:586-588.
50. Harousseau JL, **Lancet JE**, Reiffers J, Lowenberg B, Thomas X, Huguet F, Fenaux P, Zhang S, Rackoff W, De Porre P, Stone R; Farnesyltransferase Inhibition Global Human Trials (FIGHT) Acute Myeloid Leukemia Study Group. *A phase 2 study of the oral farnesyl transferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia*. *Blood*. 2007; 109:5151-5156.
51. **Lancet JE**, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. *A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia*. *Blood*. 2007; 109:1387-1394.
52. O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, Damon LE, Erba HP, Estey E, Foran J, **Lancet JE**, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. *Acute myeloid leukemia clinical practice guidelines in oncology*. *J Natl Compr Canc Netw*. 2006; 4:16-36.
53. Liesveld JL, Rosell KE, Lu C, Bechelli J, Phillips G, **Lancet JE**, Abboud CN. *Acute myelogenous leukemia--microenvironment interactions: Role of endothelial cells and proteasome inhibition*. *Hematology*. 2005; 10:483-494.
54. Raponi M, Belly RT, Karp JE, **Lancet JE**, Atkins D, Wang Y. *Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia*. *BMC Cancer*. 2004; 4:56.

55. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, **Lancet JE**, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. *Phase II study of su5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.* Clin Cancer Res. 2004; 10:88-95.
56. Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, **Lancet JE**, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. *Phase I study for poor-prognosis lymphoma: Augmentation of the "BEAM" Regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.* Semin Oncol. 2004; 31:59-61.
57. O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, **Lancet JE**, Karp JE, Albitar M, Cherrington JM, Giles FJ. *Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.* Leuk Res. 2004; 28:679-689.
58. Liesveld JL, **Lancet JE**, Rosell KE, Menon A, Lu C, McNair C, Abboud CN, Rosenblatt JD. *Effects of the farnesyl transferase inhibitor r115777 on normal and leukemic hematopoiesis.* Leukemia. 2003; 17:1806-1812.
59. Giles FJ, Stopeck AT, Silverman LR, **Lancet JE**, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. *SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.* Blood. 2003; 102:795-801.
60. Giles FJ, Cooper MA, Silverman L, Karp JE, **Lancet JE**, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. *Phase II study of su5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.* Cancer. 2003; 97:1920-1928.
61. Liesveld JL, Abboud CN, Ifthikharuddin JJ, **Lancet JE**, Wedow LA, Oliva J, Stamm CG, Nichols D. *Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.* Biol Blood Marrow Transplant. 2002; 8:662-665.
62. Karp JE, **Lancet JE**, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. *Clinical and biologic activity of the farnesyltransferase inhibitor r115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial.* Blood. 2001; 97:3361-3369.

63. **Lancet JE**, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL. *Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors*. Bone Marrow Transplant. 1998; 22:265-271.

Book Chapters and Reviews

1.  (b) (4)
2. Zhang L, Padron E, **Lancet J**. *The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes*. Leuk Res 2014; Nov 6 (Epub ahead of print).
3. **Lancet JE**. *Postremission therapy in acute promyelocytic leukemia: room for improvement?* J Clin Oncol 2014; 32:3692-3696.
4. Sweet K, **Lancet JE**. *Novel therapeutics in acute myeloid leukemia*. Curr Hematol Malig Rep. 2014; 9:109-117.
5. **Lancet JE**, Maslak P, Soignet SL. *Acute Promyelocytic Leukemia*. In: *Wintrobe's Clinical Hematology*, edited by Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, Rodgers, Foerster J. Lippincott Williams & Williams. 2014; 1656-1672.
6. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, **Lancet J**, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M; National Comprehensive Cancer Network. J Natl Compr Canc Netw 2013; 11:1047-1055
7. **Lancet JE**. *New agents: great expectations not realized*. Best Pract Res Clin Haematol. 2013; 26:269-274.
8. Komrokji RS, Padron E, **Lancet JE**, List AF. *Prognostic factors and risk models in myelodysplastic syndromes*. Clin Lymphoma Myeloma Leuk. 2013;13 Suppl 2:S295-299.
9. Kubal T, **Lancet JE**. *The thorny issue of relapsed acute myeloid leukemia*. Curr Opin Hematol. 2013; 20:100-106.
10. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, **Lancet J**, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA,

Wang ES, Gregory KM, Naganuma M. *Acute myeloid leukemia, version 2.2013*. J Natl Compr Canc Netw 2013; 11:1047-1055.

11. Duong V, **Lancet JE**. *Novel targeted therapies for acute myeloid leukemia*. In: *Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics*, edited by Tao J, Sotomayor E. Springer. 2012; 315-348.
12. Mathew RA, Bennett JM, Liu JJ, Komrokji RS, **Lancet JE**, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. *Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature*. Leuk Res 2012; 36:72-80.
13. Komrokji RS, **Lancet JE**, List AF. *Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?* Curr Hematol Malig Rep 2010; 5(1):9-14.
14. Naghashpour M, **Lancet J**, Moscinski L, Zhang L. *Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/MLL-MLLT1(ENL), B/T-lymphoid type: a first case report*. Am J Hematol 2010; 85:451-454.
15. **Lancet JE**, Shah, BD. *Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress?* American Society of Clinical Oncology Educational Book. 2009;372-377.
16. **Lancet JE**, Karp JE. *Novel postremission strategies in adults with acute myeloid leukemia*. Curr Opin Hematol. 2009;16(2):105-111.
17. **Lancet JE**, Giralt S. *Therapy for older AML patients: The role of novel agents and allogeneic stem cell transplant*. J Natl Compr Canc Netw. 2008;6(10):1017-1025.
18. Karp JE, **Lancet JE**. *Tipifarnib in the Treatment of Newly Diagnosed Acute Leukemia*. Biologics: Targets & Therapy. Dove Medical Press Limited. 2008;2(3):491-500.
19. Karp JE, **Lancet JE**. *Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies*. Cancer Invest. 2007;25:484-494.
20. Melchert M, **Lancet J**. *Acute myeloid leukemia in the elderly*. In: *Blood Disorders in the Elderly*, edited by Baducci L, Ershler W, de Gaetano G. Cambridge University Press. 2007.
21. **Lancet JE**, Karp J. *Molecular therapeutics of AML: Selected targeted approaches-farnesyltransferase*. In: *Acute Myelogenous Leukemia*, edited by Karp JE. The Humana Press. 2007.
22. Shivakumar L, **Lancet JE**. *The role of farnesyl transferase inhibitors in the treatment of patients with leukemia and myelodysplastic syndrome*. Clin Leuk. 2006; 1:80-83.

23. **Lancet JE**, Karp JE. *Farnesyl transferase inhibitors in myeloid disorders*. Oncology (Williston Park) 2005; 19:1043-1049.
24. Karp JE, **Lancet JE**. *Targeting the process of farnesylation for therapy of hematologic malignancies*. Curr Mol Med. 2005; 5:643-652.
25. Karp JE, **Lancet JE**. *Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies*. Fut Oncol. 2005;1:719-731.
26. Karp JE, **Lancet JE**. *Farnesyltransferase inhibitors (FTIs) in myeloid malignancies*. Ann Hematol. 2004;83 Suppl 1:S87-88.
27. Komrokji R, **Lancet J**, Felgar R, Wang N, Bennett JM. *Burkitt's leukemia with precursor b-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia /lymphoma). Case report and review of literature*. Leuk Res. 2003;27:561-566.
28. **Lancet JE**, Karp JE. *Farnesyl transferase inhibitors in hematologic malignancies: New horizons in therapy*. Blood. 2003;102:3880-3889.
29. **Lancet JE**, Karp JE. *Farnesyl transferase inhibitors in myeloid malignancies*. Blood Rev. 2003;17:123-129.
30. Rathnasabapathy R, **Lancet JE**. *Management of acute myelogenous leukemia in the elderly*. Cancer Control. 2003;10:469-477.
31. **Lancet JE**, Rosenblatt JD, Karp JE. *Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of zarrestra activity in high-risk leukemias*. Semin Hematol. 2002;39:31-35.
32. Karp JE, Kaufmann SH, Adjei AA, **Lancet JE**, Wright JJ, End DW. *Current status of clinical trials of farnesyltransferase inhibitors*. Curr Opin Oncol. 2001;13:470-476.
33. **Lancet JE**, Willman CL, Bennett JM. *Acute myelogenous leukemia and aging. Clinical interactions*. Hematol Oncol Clin North Am. 2000;14:251-267.
34. **Lancet JE**, Rapoport AP. *Macrocytosis*. In: *Diagnostic Strategies*, edited by Black ER, Bordley DR, Tape TG, Panzer RJ. Philadelphia, PA, American College of Physicians; 1998.

Scientific Abstracts - Plenary/Oral Presentations

1. 2014 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Stein EM, Stein A, Walter RB, Fathi AT, **Lancet JE**, Kovacovics TJ, Advani AS, DeAngelo DJ, O'Meara MM, Zhao B, Kennedy DA, Erba HP. *Interim Analysis of a*

Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia.
ASH Annual Meeting Abstracts. December 2014.

2. 2014 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Rollison DE, Shain KH, Lee JH, Hampra SS, Fisher K, Al Ali NH, Padron E, **Lancet JE**, Olesnyckyj M, Kenvin L, Knight RD, Dalton W, List AF, Komrokji RS. *Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated With or Without Lenalidomide.* ASH Annual Meeting Abstracts. December 2014.
3. 2014 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Ravandi F, Ritchie E, Sayar H, **Lancet J**, Craig MD, Vey N, Strickland SA, Schiller G, Jabbour E, Erba HP, Pigneux A, Horst H-A, Recher C, Klimek VM, Cortes J, Feldman EJ, Craig AR, Fox JA, Ward R, Smith J, Acton G, Mehta C, Kantarjian HM, Stuart RK. *Improved Survival in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).* ASH Annual Meeting Abstracts. December 2014.
4. 2014 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING.
Zeidner JF, Foster MC, Blackford A, Litzow MR, Morris L, Strickland SA, **Lancet JE**, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Greer J, Cain JM, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. *Randomized Multicenter Phase II Trial of Timed-Sequential Therapy with Flavopiridol (Alvocidib), Cytarabine, and Mitoxantrone (FLAM) Versus “7+3” for Adults with Newly Diagnosed Acute Myeloid Leukemia.* ASCO Annual Meeting Abstracts. June 2014.
5. 2013 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Jabbour E, Garcia-Manero G, Xiao L, Al Ali N, Mishra A, Padron E, **Lancet JE**, Bryan J, Prescott H, Steensma D, Sekeres MA, Roboz GJ, List A, Kantarjian HM, and Komrokji RS. *Outcome of Patients with Low and Intermediate-1 Risk MDS After Hypomethylating Failure.* ASH Annual Meeting Abstracts. December 2013.
6. 2013 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
Komrokji RS, Kulasekararaj AG, Al Ali NH, Kordasti SY, Bart-Smith E, Benjamin C, Padron E, **Lancet JE**, List A, Mufti GJ, Epling-Burnette PK. *Characteristics and Outcome of Myelodysplastic Syndromes (MDS) Patients with Autoimmune Diseases.* ASH Annual Meeting Abstracts. December 2013.
7. 2013 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
Padron E, Kunigal S, Ren X, Painter JS, Metcalf R, Johnson J, Zhang L, **Lancet JE**, Komrokji RS, Daniels K, List A, Epling-Burnette PK. *SRSF2 Mutations Impair Nuclear Aggregation and Represent a Novel Mechanism of Spliceosomal Dysregulation in CMML.* ASH Annual Meeting Abstracts. December 2013.

8. 2013 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
Garcia-Manero G, Sekeres MA, List AF, Khoury HJ, Advani A, Jabbour E, Kantarjian HM, **Lancet JE**, Cable L, Guthrie K, Hogeland G, Ptaszynski M, Maloney L, Corson, Komrokji RS. *Phase 1 Dose-Escalation/Expansion Study of ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. December 2013.
9. 2011 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Sekeres MA, Komrokji RS, **Lancet JE**, Tiu RV, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Paquette R, Smith A, Strozniak L, Alan F. List, AF, and Maciejewski JP. *Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)*. ASH Annual Meeting Abstracts. December 2011.
10. 2011 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Jaglal MV, Duong VH, Bello CM, Al Ali NH, Fernandez HF, **Lancet JE**, List AF, and Komrokji RS. *Efficacy of Cladribine, Cytarabine, G-CSF (Neupogen), Mitoxantrone (CLAG-M Regimen) Compared to Standard 3+7 (Anthracycline and Cytarabine) in Secondary Acute Myeloid Leukemia (sAML) After Azanucleosides Failure*. ASH Annual Meeting Abstracts. Dec 2011.
11. 2010 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Sekeres MA, Gundacker H, **Lancet J**, Advani A, Petersdorf S, Liesveld JL, Mulford D, Norwood T, Willman CL, List AF, and Appelbaum FR. *A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)*. ASH Annual Meeting Abstracts. December 2010.
12. 2010 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Corrales-Yepe M, Kharfan-Dabaja MA, **Lancet J**, List AF, Padron E, Rollison D, Epling-Burnette PK, Zhang L, Field T, Pinilla-Ibarz J, and Komrokji RS. *Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2010.
13. 2010 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Lancet JE, Feldman EJ, Kolitz JE, Tallman MS, Hogge DE, Komrokji. Annual Meeting Abstracts, Dec 2009. *Phase IIb multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus Cytarabine and Daunorubicin in patients with untreated AML 60-75 years of age*. ASH Annual Meeting Abstracts, December 2010.
14. 2009 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.
Lancet JE, Roboz GJ, Cripe LD, Maris M, List AF, Fox J, Michelson GC, Karp J. *Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination*

Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients. ASH Annual Meeting Abstracts December 2009.

15. 2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING. **Lancet JE**, Karp J, Cripe L, Roboz G, Wollman M, Berman C, Conroy A, Hawtin R, Fox J, Michelson G. *Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.* ASCO Annual Meeting Abstracts, June 2009.
16. 2007 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. **Lancet JE**, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS, Gojo I, Mulford D, Baer M, List AF, Multani PS, Sikick BI. *Phase I/II Study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with Pgp-positive acute myeloid leukemia (AML).* ASH Annual Meeting Abstracts, Dec 2007.
17. 2007 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. **Lancet JE**, Kantarjian H, Ravandi F, Bastien S, Alino K, Michelson G, Karp J. *SNS-595 demonstrates clinical responses in a phase I study in acute leukemia.* ASH Annual Meeting Abstracts, Dec 2007.
18. 2006 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. **Lancet JE**, Baer MR, Cripe LD, List AF, Marcelletti JF, Multani PS, Sikic BI. *Phase I/II pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with acute myeloid leukemia (AML).* ASH Annual Meeting Abstracts, December 2006.
19. 2005 EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL MEETING. **Lancet JE**, Gotlib J, Gojo I, Feldman EJ, Morris L, Liesveld JL, Kaufmann SH, Greer J, Dugan K, Adjei A, Bruzek L, Wright JJ, Greenberg PL, Karp JE. *Bone marrow response rate in elderly patients with poor-risk AML following treatment with the orally available farnesyl transferase inhibitor tipifarnib (Zarnestra, R115777).* Proc 10th Congress of the EHA, June 2005.
20. 2003 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. **Lancet JE**, Gojo I, Gotlib J, et al. *Tipifarnib (ZarnestraTM) in poor-risk previously untreated AML and MDS: interim results of a phase II trial.* ASH Annual Meeting Abstracts Nov 2003.
21. 2003 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. Harousseau JL, Reiffers J, Lowenberg B, Thomas X, Huguët F, Fenaux P, Stone RM, **Lancet J**, Arani R, Rackoff R, Thibault A. *ZarnestraTM (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): Results of a multicenter phase 2 study.* ASH Annual Meeting Abstracts, Nov 2003.

22. 2000 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING. **Lancet J**, Rosenblatt J, Liesveld JL, End D, Horak I, Ange D, Rosell K, Petronio S, Smith A, Karp J. *Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: preliminary results of a phase I trial*. ASCO Annual Meeting Abstracts, June 2000.

Scientific Abstracts - Poster Presentations

1. **Lancet JE**, Othus M, DeAngelo DJ, Coutre S, Komrokji RS, Tallman MS, Litzow MR, Appelbaum FR. *Safety and Tolerability of the Combination of ATRA + Arsenic Trioxide + Gemtuzumab Ozogamicin in High-Risk Acute Promyelocytic Leukemia: Initial Report of the SWOG/Alliance/ECOG S0535 Trial*. ASCO Annual Meeting Abstracts. May 2015
2. Padron E, Dezern AE, Vaddi K, Scherle PA, Zhang Q, Ma Y, Balasis M, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GH, **Lancet JE**, List AF, Sekeres MA, Komrokji RS. *A Multi-institution Phase I Trial of Ruxolitinib in Chronic Myelomonocytic Leukemia*. ASCO Annual Meeting Abstracts. May 2015
3. Sallman DA, Komrokji RS, Vaupel C, Al Ali N, **Lancet JE**, List AF, Hall J, Padron E. *Influence of Variant Allele Frequency on the Phenotypic Penetrance of TP53 Mutations in Myeloid Malignancies*. ASCO Annual Meeting Abstracts. May 2015
4. Schiller GJ, Ritchie EK, Sayar H, **Lancet JE**, Craig MD, Vey N, Strickland SA, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Odenike O, Craig AR, Ward R, Smith J, Kantarjian HM, Stuart RK, Ravandi F. *Allogeneic Hematopoietic Cell Transplant in Patients ≥ 60 Years of Age with First Relapsed or Refractory Acute Myeloid Leukemia After Treatment with Vosaroxin Plus Cytarabine vs Placebo Plus Cytarabine: Results from VALOR*. ASCO Annual Meeting Abstracts. May 2015
5. Rollison DE, Shain KH, Lee J-H, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, **Lancet J**, Xu Q, Knight RK, List AF, Dalton W, Komrokji R. *Lenalidomide and Risk of Acute Myeloid Leukemia Transformation Among Myelodysplastic Syndrome Patients*. ASH Annual Meeting Abstracts. Dec 2014.
6. Sallman S, Al Ali NH, Padron E, **Lancet JE**, List AF, Komrokji RS. *Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognosis and Response to Treatment*. ASH Annual Meeting Abstracts. Dec 2014.
7. Suleiman Y, Dalia S, Liu J, Bowers JW, Padron E, **Lancet JE**, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. *Clinical Prognostic Factors and Outcomes of Essential Thrombocythemia When Transformed to Myelodysplastic Syndrome and Acute Myeloid Leukemia*. ASH Annual Meeting Abstracts. December 2014.
8. Komrokji RS, Padron E, Al Ali NH, **Lancet JE**, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF. *Prognostic Value of Circulating Myeloblasts in Patients with*

Myelodysplastic Syndromes: A Proposal for Incorporation in the Revised International Prognostic Scoring System. ASH Annual Meeting Abstracts. December 2014.

9. Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, **Lancet JE**, Tinsley S, Nardelli LA, Benoit C, Pinilla-Ibarz J, Epling-Burnette PK, List AF. *A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.* ASH Annual Meeting Abstracts. December 2014.
10. Swords RT, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Greenberg PL, Cortes JE, Yarranton GT, Walling JM, **Lancet JE**. *KB004, a Novel Non-Fucosylated Humaneered Antibody, Targeting EphA3, is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies.* ASH Annual Meeting Abstracts. December 2014.
11. Eksioglu EA, Heider K-H, Rueter B, Burnette A, Wei M, McGraw K, Basiorka AA, Patel P, **Lancet J**, Komrokji R, List AF, Wei S. *Novel Therapeutic Approach to Improve Hematopoiesis by Targeting Myeloid Derived Suppressor Cells with a Humanized Anti CD33 Antibody.* ASH Annual Meeting Abstracts. December 2014.
12. Yee KWL, Savona M, Sorensen M, Brown P, Blum WG, DeAngelo DJ, Gutierrez M, Garzon R, Schuh AC, Gabrail NY, Wadleigh M, **Lancet JE**, Shah BD, Berdeda JG, Wagner-Johnston ND, Flinn I, Rashal T, Kauffman M, Shacham S, Stone RM. *A Phase I Dose-Escalation Study of the Oral Selective Inhibitor of Nuclear Export KPT-330 (Selinexor) in Patients with Relapsed/Refractory Actue Myeloid Leukemia.* ASCO Annual Meeting Abstracts. June 2014.
13. **Lancet JE**, Wei AH, Durrant STS, Hertzberg MS, Swords RT, Lewis ID, Jonas B, Cortes JE, Yarranton G, Walling JM. *A Phase I Study of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against the Receptor Tyrosine Kinase EphA3, in Advanced Hematologic Malignancies.* ASH Annual Meeting Abstracts. Dec 2013
14. Field T, Perkins J, Tomblyn M, Hillgruber R, Nishihori T, Misrha A, Pidala J, Ayala E, Locke FL, Alsina M, Betts BC, Padron E, Fernandez HF, **Lancet JE**, List A, Komrokji RS, Kharfan-Dabaja MA, and Anasetti C. *Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine.* ASH Annual Meeting Abstracts. Dec 2013
15. Zeidan AM, Al Ali NH, Kharfan-Dabaja MA, Padron E, Zhang L, Epling-Burnette PK, **Lancet JE**, List AF, Komrokji RS. *The Utility Of Newer Risk Models In Predicting Outcomes Of Patients with Higher-Risk Myelodysplastic Syndromes Treated With Azactidine.* ASH Annual Meeting Abstracts. Dec 2013

16. Komrokji RS, Corrales-Yepe MG, Al Ali NH, Padron E, **Lancet JE**, List A. *Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior to Azanucleosides*. ASH Annual Meeting Abstracts. Dec 2013
17. Tao J, Shah BD, Zhang X, Rastogi P, Tao J, **Lancet JE**, Nieder M, Lin HY, Sotomayor EM, Moscinski L, Zhang L. *Expression Level Of p-STAT5, c-MYC and IKZF1 by Immunohistochemistry Might Correlate with Adverse Clinic Outcome in Adult B-Lymphoblastic Leukemia*. ASH Annual Meeting Abstracts. Dec 2013
18. Kunigal S, Teer J, Painter J, Yoder SJ, Kim E, Zhang L, **Lancet JE**, Komrokji RS, Abdel-Wahab O, List A, Epling-Burnette PK, Padron E. *JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause of Mutation-Independent RNA Splicing Aberrancy in CMML*. ASH Annual Meeting Abstracts. Dec 2013
19. Rastogi P, Moscinski LC, Komrokji RS, Padron E, Sagatys EM, Naghashpour M, Tao J, Bennett JM, List A, **Lancet JE**, Zuckerman KS, Zhang L. *Clinical Features and Outcome of Clonal Mastocytosis Secondary to Chronic Myelomonocytic Leukemia (SM-AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study*. ASH Annual Meeting Abstracts. Dec 2013
20. Savona M, Garzon R, de Nully Brown P, Yee K, **Lancet JE**, Gutierrez M, Gabrail N, Mau-Sorensen M, Baz R, Byrd JC, Kuruvilla J, Siegel DS, Shacham S, Rashal T, Yau CYF, McCauley D, Saint-Martin J-R, McCartney J, Landesman Y, Klebanov B, Pond G, Oza AM, Kauffman M, Mirza MR, Stone RM. *Phase I Trial of Selinexor (KPT-330), a First-In-Class Oral Selective Inhibitor Of Nuclear Export in Patients with Advanced Acute Myelogenous Leukemia*. ASH Annual Meeting Abstracts. Dec 2013
21. Komrokji RS, Duong VH, Zhang L, Lee JH, Padron E, **Lancet JE**, and List A. *A Sequential Two-Stage Dose Escalation Study Evaluating the Safety and Efficacy of Eltrombopag in Thrombocytopenic Patients with Myelodysplastic Syndrome Resistant to Hypomethylating Agents*. ASH Annual Meeting Abstracts. Dec 2013
22. Ho VQ, Cade R, Wetzstein GA, Hoang VD, List A, Padron E, Fernandez HF, **Lancet JE**, Komrokji RS. *A Comparison of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin vs Idarubicin*. ASH Annual Meeting Abstracts. Dec 2013
23. Komrokji RS, Apuri S, Al Ali N, Padron E, Pinilla-Ibarz J, Ho V, List AF, **Lancet JE**. *Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes*. ASCO Annual Meeting Abstracts. June 2013
24. Feldman EJ, **Lancet JE**, Kolitz JE, Hogge D, Tallman MS, Goldberg SL, Kovacovics T, Louie AC, Cortes JE. *Multivariate Analysis of Factors Affecting Overall Survival, Event Free Survival, and 60-Day mortality Among AML Patients Treated with CPC-351 or Intensive Chemotherapy*. ASCO Annual Meeting Abstracts. June 2013

25. **Lancet JE**, Cortes J, Kvasovics T, Hogge D, Kolitz JE, Tallman MS, Chiarella M, Louie A, Feldman E. *A Comparison of CR vs CRi Response Following CPX-351 Treatment of Newly Diagnosed AML in Elderly Patients*. ASCO Annual Meeting Abstracts. June 2012.
26. Raza A, Komrokji RS, Brooks R, **Lancet JE**, List AF, Ren C, Taft DR, Wilhelm F, Maniar M. *A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes*. ASCO Annual Meeting Abstracts. June 2012.
27. Sweet KL, Komrokji RS, Al Ali N, Crescentin RM, Domingo G, Chavez JC, Dalia S, Tinsley S, **Lancet J**, Zhang L, Pinilla-Iberz J. *Impact of ABL kinase domain mutations on the outcome of patients with chronic myeloid leukemia*. ASCO Annual Meeting Abstracts. June 2012.
28. Ravandi F, Ritchie EK, Sayar H, Strickland SA, Craig M, Selleslag DLD, Maertens J, Havelange V, **Lancet JE**, Ketchum SB, Acton G, Mehta CR, Silva E, Craig A, Fox JA, Stuart RK, Erba HP, Vey N, Schiller GH, Feldman EJ. *VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia*. ASCO Annual Meeting Abstracts. June 2012.
29. Khan AM, **Lancet JE**, Kharfan-Dabaja MA, Al Ali N, List AF, Komrokji RS. *Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia*. ASCO Annual Meeting Abstracts. June 2012.
30. Domingo GC, Dalia S, Chavez JC, Carballido EM, Aguayo-Hiraldo PI, Sweet KL, Crescentini RM, Sokol L, Cultrera JL, Shah BD, **Lancet JE**, Sotomayor EM, Komrokji RS, Pinilla-Ibarz J. *Impact of immunoglobulin heavy chain variable region mutational status on the outcome of patients with chronic lymphocytic leukemia harboring isolated 13q deletion*. ASCO Annual Meeting Abstracts. June 2012.
31. Dalia S, Chavez JC, Domingo G, Carballido EM, Aguayo-Hiraldo PI, Sweet KL, Crescentini RM, Sokol L, Bello CM, Cultrera JL, Shah BD, **Lancet JE**, Komrokji RS, Sotomayor EM, Pinilla-Ibarz J. *Incidence of second and secondary malignancies in patients with CLL: A single institution experience*. ASCO Annual Meeting Abstracts. June 2012.
32. Komrokji RS, Khan AM, Ali NHA, List AF, **Lancet JE**. *Impact of Red Blood Cell (RBC) Transfusion During Induction Chemotherapy in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML)*. ASH Annual Meeting Abstracts. Dec 2011.
33. Sweet KL, Crescentini RM, II, **Lancet JE**, Komrokji RS, Cultrera JL. *Outcomes and Prognostic Factors in Adolescents and Young Adults Undergoing Intensive Therapy for Acute Lymphoblastic Leukemia*. ASH Annual Meeting Abstracts. Dec 2011.

34. **Lancet JE**, Sekeres MA, Wood BL, Grove LE, Sandalic L, Sievers EL, and Jurcicet JG. *Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study*. ASH Annual Meeting Abstracts. Dec 2011.
35. Komrokji RS, Rollison DE, Al Ali NH, Corrales-Yepe M, Epling-Burnette PK, **Lancet JE**, and List AF. *Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2011.
36. Komrokji RS, List AF, Wilhelm F, **Lancet JE**, Raza A. *Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) - Phase I Study Results*. ASH Annual Meeting Abstracts. Dec 2011.
37. Komrokji RS, List AF, Khoury HJ, **Lancet JE**, Jabbour E, Foudray MC, Winski SL, Bell S, Rush SA, Lara Maloney, Ptaszynski AM, Kantarjian HM, and Garcia-Manero, G. *Phase I Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2011.
38. **Lancet JE**, Komrokji RS, Yu D, Advani AS, Searles T, Sekeres MA, and List AF. *A Phase I Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML)*. ASH Annual Meeting Abstracts. Dec 2011.
39. Komrokji RS, Pinilla-Ibarz J, Yu D, Nardelli L, Cubitt C, Zhao X, Fernandez HF, List AF, and **Lancet JE**. *A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia*. ASH Annual Meeting Abstracts. Dec 2011
40. Komrokji RS, Ali NHA, Padron E, **Lancet JE**, List AF. *Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q*. ASH Annual Meeting Abstracts. Dec 2011.
41. Komrokji RS, Ali NHA, Padron E, **Lancet JE**, List AF. *Impact of Iron Chelation Therapy on Overall Survival and AML Transformation in Lower Risk MDS Patients Treated At the Moffitt Cancer Center*. ASH Annual Meeting Abstracts. Dec 2011.
42. Komrokji RS, Ali NH, Corrales-Yepe M, Padron E, Epling-Burnette PK, **Lancet JE**, and List A. *Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2011.
43. Komrokji RS, Al Ali NH, Alrawi E, Padron E, Perkins J, Field T, **Lancet JE**, and List AF. *Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome*. ASH

Annual Meeting Abstracts. Dec 2011.

44. Komrokji RS, List AF, Yu D, et al. Fulp WJ, Rodriguez Y, Smith PS, and **Lancet JE**. *A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2011.
45. Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Jamil Ahmed J, Komrokji RS, **Lancet JE**, List AF, McNeel DJ, Dessureault S, Antonia S, Sotomayor EM, Epling-Burnette PK, and Pinilla-Ibarzet J. *Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome*. ASH Annual Meeting Abstracts. Dec 2011.
46. Duong VH, Jaglal MV, Zhang L, Kale, V, **Lancet JE**, Komrokji RS, and List A. *Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy*. ASH Annual Meeting Abstracts. Dec 2011.
47. **J. E. Lancet**, J. E. Cortes, T. Kovacovics, D. Hogge, J. E. Kolitz, M. S. Tallman, M. Chiarella, A. C. Louie, E. J. Feldman. *CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML)*. ASCO Annual Meeting Abstracts. June 2011.
48. **Lancet JE**, Feldman EJ, Cortes JE, Hogge D, Tallman MS, Kovacovics T, Louie AC. *CPX-351 in AML after failed induction with cytarabine and daunorubicin*. ASCO Annual Meeting Poster Abstracts. June 2010.
49. Roboz GJ, **Lancet JE**, Cripe LD, Kashani FR, List AF, Fox A, Michelson G, Karp JE. *Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination vorloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia*. ASCO Annual Meeting Abstracts. June 2010.
50. **Lancet JE**, Smith BD, Bradley R, Komrokji RS, Teofilovici F, Rizzieri D. *A Phase I/2 study of the potent Hsp 90 inhibitor STA-9090 administered once weekly in subjects with hematologic malignancies*. ASH Annual Meeting Abstracts. Dec 2010
51. Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, Komrokji RS, **Lancet JE**, Kim J, Ayala E, Alsina M, ochoa-Bayona JL, List AF, Anasetti C. *Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML*. ASH Annual Meeting Abstracts. Dec 2010.
52. Reljic T, Bhansali N, Komrokji RS, Lin K, List AF, Djulbegovic B, Fenstermacher DA, **Lancet JE**, Miladinovic B, Kumar A. *Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2010.

53. Lin K, Reljic T, Kumar A, **Lancet JE**, List AF, Komrokji RS. *Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure*. ASH Annual Meeting Abstracts. Dec 2010.
54. Padron E, Komrokji RS, **Lancet JE**, List AF, Dessureault S, Antonia S, Ahmed J, Patel S, Powers J, Bai F, Sotomayor EM, Epling-Burnette PK, Pinilla-Ibarz J. *A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS)*. ASH Annual Meeting Abstracts. Dec 2010.
55. Teichman ML, Wetzstein GA, Ho VQ, **Lancet JE**, List AF, Komrokji RS. *Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia*. ASH Annual Meeting Abstracts. Dec 2010.
56. Bowers JW, Liu J, Zuckerman KS, Naghashpour M, **Lancet JE**, Komrokji RS, Moscinski LC, and Zhang L. *Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Transformation From Essential Thrombocythemia (ET) In Patients Treated with Hydroxyurea or Anagrelide: A Single Center Series of 17 Cases*. ASH Annual Meeting Abstracts. Dec 2010.
57. Corrales-Yepe M, **Lancet JE**, List AF, Kharfan-Dabaja MA, Field T, Padron E, Komrokji RS. *Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes*. ASH Annual Meeting Abstracts. Dec 2010.
58. Komrokji RS, **Lancet JE**, Yu D, Santana E, Yan L, Smith PS, Tinsley S, Deaver D, Zhang L, List AF. *Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study*. ASH Annual Meeting Abstracts. Dec 2010.
59. **Lancet JE**, Smith BD, Bradley R, Komrokji RS, Teofilovici F, Rizzieri DA. *A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies*. ASH Annual Meeting Abstracts. Dec 2010.
60. George TJ, Woolery JE, Wetzstein GA, Ho VQ, **Lancet JE**, List AF, Komrokji RS. *A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population*. ASH Annual Meeting Abstracts. Dec 2010.
61. Veliz M, Powers J, Zhang L, Santana E, **Lancet JE**, Komrokji RS, Kharfan-Dabaja M, Tinsley S, Deaver D, Sotomayor ES, Pinilla-Ibarz J. *Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL*. ASH Annual Meeting Abstracts. Dec 2010.
62. Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, **Lancet JE**, Komrokji RS, ochoa-Bayona JL, Alsina M, Ayala E, Kim J, List AF,

Anasetti C. *Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor.* ASH Annual Meeting Abstracts. Dec 2010.

63. Wetzstein GE, George TJ, Sharifi M, Hoang VD, Ho VQ, Quilitz RE, Spears DA, Komrokji RS, List AF, **Lancet JE**, Greene JN. *Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.* ASH Annual Meeting Abstracts. Dec 2009.
64. Vigil C, Cortes J, Kantarjian HM, Garcia-Manero G, **Lancet JE**, List AF. *Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients.* ASH Annual Meeting Abstracts. Dec 2009.
65. Veliz M, Santana R, **Lancet JE**, Komrokji RS, Kharfan-Dabaja MA, Power JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J. *Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.* ASH Annual Meeting Abstracts. Dec 2009..
66. Advani A, Gundacker H, Sala-Torra O, Radich J, Lai R, Slovak ML, **Lancet JE**, Coutre S, Stuart RK, Mims MP, Stiff P, Appelbaum FR. *Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.* ASH Annual Meeting Abstracts. Dec 2009.
67. Price SL, George TJ, Wetzstein GA, **Lancet JE**, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. *Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?* ASH Annual Meeting Abstracts. Dec 2009.
68. **Lancet JE**, Feldman EJ, Kolitz JE, Tallman MS, Hogge DE, Komrokji RS, Chiarella MT, Louie AC. *Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.* ASH Annual Meeting Abstracts. Dec 2009.
69. List AF, Rocha K, Zhang L, Komrokji RS, Clark J, Caceres G, Billingsley D, Sokol L, **Lancet JE**, Maciejewski JP, Sekeres MA, Chen X, Wei S. *Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression.* ASH Annual Meeting Abstracts. Dec 2009.
70. Field T, Perkins J, Kharfan-Dabaja MA, Fernandez HF, Perez L, ochoa-Bayona JL, **Lancet JE**, Komrokji RS, Alsina M, Ayala E, List AF, Anasetti C. *Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.* ASH Annual Meeting Abstracts. Dec 2009.

71. Komrokji RS, Kharfan-Dabaja MA, Price SL, Wetzstein GA, List AF, Fernandez AF, Fernando HF, George TJ, Pinilla-Ibarz J, Ho VQ, **Lancet JE**. Albumin Is a Prognostic Factor for Response and Overall Survival in Relapsed or Refractory Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts. Dec 2009.
72. Shah BD, Veliz M, Santana R, **Lancet JE**, Powers JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla J. Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. Dec 2009.
73. **Lancet JE**, Komrokji RS, Lin H, de Castro CM, Rizzeri DA, Melchert M, List A. *Maintenance therapy with low-dose subcutaneous 5-azacitidine in older patients with AML in 1st remission.* ASH Annual Meeting Abstracts. Dec 2009.
74. Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, **Lancet JE**. *Phase I study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancy.* ASH Annual Meeting Poster Session 2008.
75. Wetzstein, GA, **Lancet JE**, Kallner JE, Sivik JM, Ho VQ, George TJ, Desai S, Fisher S, Newton MD, List AF. *Safety, feasibility, and cost-effectiveness with outpatient administration of high-dose cytarabine consolidation in acute myeloid leukemia.* ASH Annual Meeting Poster Session 2008.
76. **Lancet JE**, Karp JE, Cripe LD, Roboz GJ, Suster M, Tan N, Hawtin R, Fox J, Berman C, Michelson G. *Voreloxin (formerly known as SNS-595) in combination with cytarabine demonstrates preliminary clinical responses in a phase I study in relapsed/refractory acute myeloid leukemia.* ASH Annual Meeting Poster Session 2008.
77. **Lancet JE**, Yu J, Saba H, Lush R, Schmidt M, Wride K, Knight R, List AF. *Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures.* ASCO Annual Meeting Poster Session 2008.
78. Ravandi F, **Lancet JE**, Giles F, Plunkett W, Williams B, Burton M, Faderl Stefan, Estrov Z, Barthakur G, Akinsanmi L, Kantarjian H. *Phase I study of triciribine phosphate monohydrate, a specific inhibitor of AKt phosphorylation, in adult patients with advanced hematologic malignancies.* ASH Annual Meeting Abstracts. June 2007.
79. **Lancet J**, Nichols G, Assouline S, Ward R, Burton M, Mintz M, Rousseau C, Kalita A, Brabant PJ, Odenike O. *A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS).* J Clin Oncol ASCO Annual Meeting Abstracts June 2007.

80. Liesveld JL, **Lancet JE**, Rosell KE, Bechelli J, Abboud CN, Phillips GL. *The CXCR4 antagonist, AMD3100, inhibits AML trans migratory activity but does not alter blast proliferation or survival.* ASH Annual Meeting Abstracts. November 2004.
81. Gotlib J, Loh M, **Lancet JE**, Vattikuti S, Quesada S, Dugan K, Katamneni U, Sridhar K, Wright J, Thibault A, Rybak ME, Shannon KM, Greenberg PL. *Phase I/II study of tipifarnib (ZARNESTRA™, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): interim results.* ASH Annual Meeting Abstracts. November 2003.
82. Raponi M, Belly R, Atkins D, Thibault A, Rackoff W, Rybak ME, Wright J, Rosenblatt J, **Lancet J**, Karp J, Harousseau JL, Stone R, and Wang Y. *Pharmacogenomic analysis reveals signaling pathways modulated by R115777 (zarnestra) in acute myeloid leukemia.* Proc Am Soc Clin Oncol 2002.
83. Liesveld JL, Rosell KE, Mc Nair C, **Lancet JE**, Abboud CN. *Endothelial coculture consistently increase acute myelogenous leukemia blast survival in vitro.* Blood 100:553a, 2002.
84. Liesveld JL, Abboud CN, **Lancet J**, Ifthikharuddin JJ, Oliva J, Wedow LA, Stamm C, Nichols D. *Oral valacyclovir vs. intravenous acyclovir in prevention of herpes simplex virus infections in autologous stem cell transplantation patients.* Blood 98:11,1652a, 2001.
85. Maher A, Smolich B, Cherrington J, O'Farrell M, Karp J, Stopeck A, Zangari M, **Lancet J**, Silverman L, Giles F. *Effects of SU5416 on angiogenic factors, proliferation, and apoptosis in patients with hematologic malignancies.* Blood 98:11, 464a, 2001.
86. Zangari M, Stopeck AT, Karp J, **Lancet J**, Silverman L, Smolich B, Cherrington J, Jacobs M, Albitar M, and Giles F. *Phase II study of SU5416 in patients with multiple myeloma.* Blood 98:11, 693a, 2001.
87. Karp JE, Stopeck A, Albitar M, Silverman L, **Lancet JE**, Jacobs M, O'Farrell M, Hannah A, Cherrington J, and Giles F. *Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase inhibitor SU5416 in refractory acute myelogenous leukemia and myelodysplasia.* Blood 98:11, 495a, 2001.
88. **Lancet JE**, Ryan CP, Abboud CN, et al. *Differences in expression of signal transduction molecules between normal and leukemic bone marrow.* ASH Annual Meeting Abstracts. Dec 2001.
89. **Lancet JE**, Liesveld JL, Ludlow J, Rosell KE, Smith AJ, Abboud CN, Karp JE, Horak I, and Rosenblatt JD. *Effects of farnesyl transferase inhibitor R115777 on hematopoiesis, leukemic cell proliferation, and signaling through the mitogen-activated protein kinase (MAPK) pathway.* Blood 94: Suppl 1, 3835a, 1999.

Invited Presentations

1. Visiting Lecturer: United States Food and Drug Administration, Silver Spring, MD. Acute Myeloid Leukemia Symposium - Identification and Management of Patients with AML Who Are Unfit for Standard Induction Therapy. 15 July 2015.
2. Visiting Lecturer: United States Food & Drug Administration, Silver Spring, MD. *Why Can't We Get a New Drug Approved in AML?* 18 July 2014.
3. Visiting Professor Lecture Series: Treatment of Older Adults with AML. George Washington University, Washington, DC. *Rethinking the Treatment of Older Adults with Acute Myeloid Leukemia*. 20 June 2014
4. ION Solutions – ASH Review Meeting, Orlando, FL. *Acute Leukemias*. 25 Jan 2014.
5. Spring 2013 NCI CTEP Early Drug Development Meeting, Bethesda, MD. *Tipifarnib in Newly-Diagnosed Acute Myelogenous Leukemia with 2-Gene Expression Signature Ratio*. 22 Apr 2013.
6. Acute Leukemia Forum 2013, San Francisco, CA. *New Agents in AML: Great Expectations not Realized*. 19 Apr 2013.
7. ION Solutions – ASH Review Meeting, Orlando, FL. *Acute Myeloid Leukemia*. 26 Jan 2013.
8. 9th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies, Orlando, FL. *Insight into the Management of the Elderly AML Patient*. 19 Jan 2013
9. 49th ASH Annual Meeting and Exposition, Atlanta, GA. *AML in the Elderly: Making the Best of a Bad Situation*. Satellite Symposia – The Changing Faces of MDS and AML. 7 Dec 2012.
10. George Washington University, Washington, DC (Division of Hematology-Oncology Grand Rounds). *Chronic Myeloid Leukemia*. 20 April 2012
11. Highlights of ASH Symposium 2011, New York, NY. *Acute Myeloid Leukemia*. 3 Feb 2012
12. Highlights of ASH Symposium 2011, Orlando FL. *Acute Myeloid Leukemia*. 20 Jan 2012
13. University of Arkansas Cancer Center, Little Rock, AR (Hematology-Oncology Grand Rounds) *Essential Therapeutic Principles Across the AML Spectrum*. 30 Nov 2011

14. Chemotherapy Foundation Symposium on Innovative Cancer Therapy for Tomorrow, New York, NY. *Studies of CPX-351 in AML*. 9 Nov 2011
15. 2nd Annual Florida Oncology Symposium, Naples FL. *AML in the Elderly: New Therapies*. 6 May 2011
16. Wake Forest University, Winston-Salem, NC (Hematology-Oncology Grand Rounds). *Risk Stratification and Treatment Principles in AML*. 21 Feb 2011
17. Moffitt Cancer Center, Department of Blood and Marrow Transplant, Tampa FL (Grand Rounds). *AML in the Elderly: Can We Raise the Bar?* October 2010
18. Fall 2010 NCI CTEP Early Drug Development Meeting, Bethesda, MD. *New Treatments in AML* 27 September 2010.
19. 45th American Society of Clinical Oncology Annual Meeting, Chicago, IL. *High Risk AML and MDS in the Elderly: Are We Making Progress?* Oral Symposium Discussant. June 2010.
20. Cleveland Clinic, Cleveland OH (Cancer Center Grand Rounds). *Management of AML in the Elderly: Can We Raise the Bar?* April 2010.
21. 44th American Society of Clinical Oncology Annual meeting, Orlando, FL. *Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress?* Educational Session, June 2009.
22. MD Anderson Cancer Center, Department of Leukemia, Houston TX (Grand Rounds). *Progress in AML Treatment: Are We Getting Anywhere Yet?* June 2008.
23. University of Cincinnati, Cincinnati, OH (Cancer Center Grand Rounds). *New Developments in AML*. May 2008.
24. University of Miami, Sylvester Cancer Center, Miami FL (Cancer Center Grand Rounds). *New Developments in AML*. April 2008.
25. 49th ASH Annual Meeting and Exposition, Atlanta, GA. *Improving Outcomes in Acute Myeloid Leukemia*. Satellite Symposia. Invited Speaker. December 2007.
26. Oncology Best Practices 2007, Moderator: Tampa, FL. *Community Based-Learning*. April 2007.
27. 11th Annual International Congress on Hematologic Malignancies, Whistler, British Columbia (oral presentation). *Farnesyltransferase Inhibitors in Leukemia; Emerging Agents in MDS*. February 2007.

Jeffrey E. Lancet, M.D.

28. 10th Annual International Congress on Hematologic Malignancies, Whistler, British Columbia (oral presentation). *Farnesyl Transferase Inhibitors in MDS*. February 2006.
29. Roswell Park Cancer Institute, Buffalo, NY (Cancer Center Grand Rounds). *Farnesyl Transferase Inhibitors in AML*. December 2005.
30. Leesburg Regional Medical Center, Leesburg, FL (Grand Rounds). *Progress in myelodysplastic syndromes*. November 2005.
31. Florida Cancer Specialists Annual Retreat, Naples, FL (Keynote Speaker). *Progress in myelodysplastic syndromes*. September 2005.
32. Geriatric Neoplasia: Leukemia, Lymphoma, Myeloma. Bari, Italy. *Progress in Myelodysplastic Syndrome*. May 2005.
33. International Congress on Hematological Malignancies, Whistler, British Columbia. *FTI in previously untreated AML*. February 2003.
34. International Congress on Hematological Malignancies, Whistler, British Columbia. *FTI and Other New Therapies in AML*. February 2002.
35. Acute Leukemias IX – Basic Research, Experimental Approaches, and Novel Therapies, Munich, Germany. *Farnesyl Transferase Inhibitors in Leukemia*. February 2001.
36. University of Rochester Cancer Center Grand Rounds, Rochester, NY. *Considerations in the Clinical Application of Signal Transduction Inhibition in AML*. January 2001.
37. Third Annual Regional Consortium for Biological Therapy of Cancer, Hershey, PA. *Effects of Farnesyl Transferase Inhibitors on Hematopoiesis and Hematologic Malignancies*. February 2000.